망막혈관종성증식에서 유리체강내 라니비주맙과 애플리버셉트 주입술의 단기 임상결과 비교
Comparison of Short-Term Clinical Outcomes between Intravitreal Ranibizumab and Aflibercept in Retinal Angiomatous Proliferation
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
목적: 망막혈관종성증식에서 유리체강내 라니비주맙과 애플리버셉트 주입술을 이용하여 치료한 6개월의 임상 결과를 보고하고자 한다. 대상과 방법: 망막혈관종성증식으로 진단 후 유리체강내 라니비주맙 혹은 애플리버셉트 주입술로 치료 받은 31안(28명)을 대상으로후향적 의무기록 분석을 시행하였다. 진단 후 1개월 간격으로 3회의 주사 후, 이후에는 재발하는 경우 추가 치료를 시행하였다. 치료전 및 첫 번째 주사 후 3, 6개월에 최대교정시력 및 중심망막두께를 측정하여 비교하였다. 결과: 라니비주맙군은 16안, 애플리버셉트군은 15안이었다. 치료 전 및 치료 후 3개월, 6개월에 측정된 평균 최대교정시력(logMAR)은라니비주맙군에서 0.78 ± 0.50, 0.47 ± 0.30, 0.59 ± 0.41, 애플리버셉트군에서 0.96 ± 0.52, 0.83 ± 0.52, 0.74 ± 0.56이고, 평균 중심망막두께는 라니비주맙군에서 315.75 ± 115.44, 188.38 ± 57.33, 218.50 ± 96.49 μm, 애플리버셉트군에서 249.00 ± 74.88, 143.73 ± 32.73, 196.73 ± 94.08 μm였다. 두 군 모두에서 진단 후 6개월에 측정된 최대교정시력은 진단 당시와 비교하여유의하게 호전되었으며(p＜0.05), 중심망막두께 역시 유의하게 감소하였다(p＜0.05). 두 군 사이에 시력(p=0.770) 및 중심망막두께(p=0.470)의 감소 정도는 유의한 차이가 없었다. 결론: 유리체강내 라니비주맙 혹은 애플리버셉트 주입술은 망막혈관종성증식 환자에서 시력을 호전시키고 황반두께를 정상화시키는데 효과적인 방법으로 생각된다.
Abstract
Purpose: To evaluate the 6-month outcomes of intravitreal ranibizumab and aflibercept treatment for patients with retinal angiomatous proliferation (RAP). Methods: A retrospective review of medical records of 28 patients (31 eyes) diagnosed with RAP was performed. All patients were initially treated with 3 consecutive intravitreal ranibizumab or aflibercept injections after diagnosis. Additional treatment was performed when exudation recurred. The best-corrected visual acuity (BCVA) and central foveal thickness were measured before the first injection and 3 and 6 months after the first injection. The values measured before the treatment were compared with those after treatment. Results: Sixteen eyes were treated with ranibizumab and 15 eyes with aflibercept. The logarithm of minimal angle of resolution (log MAR) values of BCVA before the first injection and 3 and 6 months after the first injection were 0.78 ± 0.50, 0.47 ± 0.30 and 0.59 ± 0.41 in the ranibizumab group and 0.96 ± 0.52, 0.83 ± 0.52 and 0.74 ± 0.56 in the aflibercept group, respectively. Central foveal thickness was 315.75 ± 115.44, 188.38 ± 57.33 and 218.50 ± 96.49 μm in the ranibizumab group and 249.00 ± 74.88, 143.73 ± 32.73 and 196.73 ± 94.08 μm in the aflibercept group, respectively. BCVA was significantly improved and central foveal thickness was significantly reduced at 6 months (p < 0.05) compared to measurements before the first injection in both groups. However, BCVA improvement and central foveal thickness were not significantly different between the 2 groups. Conclusions: Both intravitreal ranibizumab and aflibercept treatments were beneficial for both normalizing macular thickness and improving visual acuity in patients with RAP. The efficacy of the 2 drugs was not noticeably different.
참고문헌 (21)
- Yannuzzi LA., "Retinal angiomatous proliferation in age-related macular degeneration", Retina, 21, pp.416~434 (2001)
- Liu Y., "Subtype lesions of neovascular age-related macular degeneration in Chinese patients", Graefes Arch Clin Exp Ophthalmol, 245, pp.1441~1445 (2007)
- Maruko I., "Clinical characteristics of exudative age-related macular degeneration in Japanese patients", Am J Ophthalmol, 144, pp.15~22 (2007)
- Massacesi AL., "The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization", Graefes Arch Clin Exp Ophthalmol, 246, pp.89~92 (2008)
- Reche-Frutos J., "Retinal angiomatous proliferation reactivation 6 months after high-dose intravitreal acetonide triamcinolone and photodynamic therapy", Eur J Ophthalmol, 17, pp.979~982 (2007)
- Saito M., "Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation", Am J Ophthalmol., 149, pp.472.e1~481.e1 (2010)
- Krebs I., "Retinal angiomatous proliferation : combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone", Graefes Arch Clin Exp Ophthalmol, 246, pp.237~243 (2008)
- Han Joo Cho, "Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation", Graefe's Archive for Clinical and Experimental Ophthalmology, 254(1), pp.23~30 (2016), Springer Nature[DOI]
- Gharbiya M., "Intravitreal anti-vascular endothelial growth factor for retinal angiomatous proliferation in treatment-naive eyes : long-term functional and anatomical results using a modified PrONTO-style regimen", Retina, 34, pp.298~305 (2014)
- 김덕배, "망막혈관종성증식 환자에서 유리체강내항혈관내피세포성장인자 주입술의 12개월 임상결과", 대한안과학회지, 54(11), pp.1700~1707 (2013), 대한안과학회
- Heier JS., "Intravitreal aflibercept(VEGF trap-eye)in wet age-related macular degeneration", Ophthalmology, 119, pp.2537~2548 (2012)
- Bakall B., "Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab", Am J Ophthalmol, 156, pp.15.e1~22.e1 (2013)
- Cho H., "Aflibercept for exudative AMD with persistent fluid on ranibizumab and", or bevacizumab, 2013, pp.97, 1032~1035
- Yonekawa Y., "Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration", Am J Ophthalmol, 156, pp.29.e2~35.e2 (2013)
- Kawashima Y., "Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy", Graefes Arch Clin Exp Ophthalmol, 253, pp.1471~1477 (2015)
- Oishi A., "One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome", Am J Ophthalmol, 159, pp.853.e1~860.e1 (2015)
- Tsaousis KT., "Intravitreal aflibercept treatment of retinal angiomatous proliferation : a pilot study and short-term efficacy", Graefes Arch Clin Exp Ophthalmol, 253, pp.663~665 (2015)
- Riusala AM., "Predictors of structural findings in old disciform lesions", Am J Ophthalmol, 138, pp.245~253 (2004)
- Shin JY., "Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients", Retina, 34, pp.2359~2366 (2014)
- Stewart MW., "Predicted biological activity of intravitreal VEGF Trap", Br J Ophthalmol, 92, pp.667~668 (2008)
- Browning DJ., "Aflibercept for age-related macular degeneration: a game-changer or quiet addition?", Am J Ophthalmol, 154, pp.222~226 (2012)